-
experimental systems, ranging from molecular screening tools, state-of-the-art methods for molecular/cellular characterization, animal models, and primary human cell/organoid models. We offer a unique
-
therapies may not rely on ex vivo handling of cell products but rather facilitate the correction of stem cells directly in the bone marrow. Based on novel CRISPR-based gene editing technology, the goal is to
-
/Cas gene editing (including prime editing), design tools, handling and editing of hematopoietic stem cells, related mouse work, and a subset of genetic analyses of engineered cell populations. As a
-
inflammation. The data sources are registry data, cohort phenotypes, single-cell transcriptomics and microbiomes. Expected start date and duration of employment This is a 3–year position from October 1, 2025
-
, through cellular, to tissue, organ and organism levels of organisation, and is coordinated by LINXS Institute of advanced Neutron and X-ray Science. AMBER is funded by the EU Marie Skłodowska-Curie (MSCA
-
related to the position, e.g. cell technology or biomaterials science. Strong experience in animal studies and collection of samples for biological and 3D imaging analysis. Ability to plan and manage